The ADA’s Own Definition of Remission Just Hit a Wall
The American Diabetes Association’s own consensus definition of type 2 diabetes remission — HbA1c < 6.5% for at least 3 months, off all glucose-lowering medication — just turned five years old, and a growing body of 2026 evidence shows that the vast majority of patients on mainstream diabetes drugs never get close to meeting it. […]
Stanford Just Found Why GLP-1s Don’t Work for 1 in 10 People
Stanford researchers just published findings that roughly 1 in 10 people carry genetic variants that make GLP-1 receptor agonist drugs — Ozempic, Mounjaro, Wegovy — meaningfully less effective at lowering blood sugar. The Stanford Medicine News report describes a meta-analysis of three clinical trials showing that carriers of specific variants in the PAM gene reach […]
Generic Dapagliflozin Just Got Approved.
The FDA has approved generic versions of dapagliflozin, a workhorse Type 2 diabetes medication in the SGLT2 inhibitor class, and the coverage has been almost entirely about access. Lower cost. More refills. Fewer prior-authorization fights at the pharmacy counter. For the millions of adults in the US who take a daily SGLT2 inhibitor to lower […]
ADA 2026 Made Multimorbidity the Headline.
At the 2026 ADA Scientific Sessions in New Orleans, a team from Leicester launched a three-paper Lancet Series on cardiometabolic multimorbidity — and the agenda tells you exactly where the diabetes conversation is right now. What the Lancet Series Covers The Leicester/NIHR ARC East Midlands team presented three new papers in The Lancet on June […]
The ADA Just Rewrote Its Standards of Care. It Still Won’t Reverse Diabetes.
The most influential diabetes document in America just dropped. The American Diabetes Association’s 202 Standards of Care in Diabetes — published in December 2025 in Diabetes Care (Volume 49, Supplement 1) and now in effect across U.S. endocrinology practices — is the annual clinical playbook that 90%+ of American endocrinologists follow when treating Type 2 […]
This New GLP-1 Pill Hit 89.6% A1c Goal — It Doesn’t Reverse Diabetes
The American Diabetes Association’s 2026 Scientific Sessions wrapped last week in New Orleans, and the headlines read like a victory lap. A new once-daily oral GLP-1 called elecoglipron — a small-molecule pill, no injection, no fasting window — sent 89.6% of patients in its phase 2b trial to an A1c of 7.0% or below. Up […]
UK Doctors Just Made GLP-1s First-Line. 17,000 Lives Saved — and Counting
The UK’s National Institute for Health and Care Excellence (NICE) just rewrote the rulebook for Type 2 diabetes. As of this year, GLP-1 receptor agonists and SGLT-2 inhibitors are being prescribed earlier, faster, and to more patients than ever before — and the agency estimates this shift could prevent around 17,000 deaths over the next […]